Medicare to Negotiate Lower Prices for Weight-Loss Drugs
That would slow the growth of the government’s spending on obesity drugs even as more people on Medicare started using them.
New prices for the 10 drugs in the first round of price negotiations were announced last summer. Those prices will go into effect next year.
Drugmakers were relieved that those cuts were not deeper. They have sued, unsuccessfully, to block the price negotiation program.
Drugs Selected for Medicare’s Second Round of Price Negotiations
Prices will go into effect in 2027.
1. Ozempic, Rybelsus and Wegovyfor diabetes and obesity
2. Trelegy Elliptafor lung conditions
3. Xtandi, for prostate cancer
4. Slow downfor blood cancer
5. Ibrancefor breast cancer
6. Ofevfor lung conditions
7. Linzessfor gastrointestinal conditions
8. Calquencefor blood cancers
9. Austedo and Austedo XRfor neurological diseases
10. Breo Elliptafor lung conditions
11. Traditionalfor diabetes
12. Xifaxanfor liver and gastrointestinal problems
13. Vraysfor depression
14. Janumet and Janumet XRfor diabetes
15. Otezlafor inflammatory conditions
